0000000000496213

AUTHOR

Ajlan Atasoy

showing 2 related works from this author

EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INN…

2016

TPS4133Background: Approximately 10-20% of patients with gastric cancer (GCa) have HER-2 positive tumors. The addition of T to cisplatin/fluoropyrimidine-based CT improved survival in metastatic HE...

OncologyCisplatinCancer Researchmedicine.medical_specialtybusiness.industryImproved survivalCancermedicine.disease03 medical and health sciences0302 clinical medicineOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinePerioperative chemotherapymedicine030211 gastroenterology & hepatologyPertuzumabStomach cancerbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

64. EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION …

2016

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryGeneral Medicinemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTrastuzumab030220 oncology & carcinogenesisPerioperative chemotherapyInternal medicinemedicineSurgeryPertuzumabStomach cancerbusinessmedicine.drugEuropean Journal of Surgical Oncology (EJSO)
researchProduct